These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 18223473

  • 21. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level.
    Takeuchi H, Matsuno N, Hirano T, Toraishi T, Konno O, Nakamura Y, Iwamoto H, Hama K, Unezaki S, Nagao T.
    Transplant Proc; 2008 Sep; 40(7):2240-2. PubMed ID: 18790203
    [Abstract] [Full Text] [Related]

  • 22. Population pharmacokinetics of sirolimus in kidney transplant patients.
    Ferron GM, Mishina EV, Zimmerman JJ, Jusko WJ.
    Clin Pharmacol Ther; 1997 Apr; 61(4):416-28. PubMed ID: 9129559
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients.
    Sánchez Fructuoso A, Ruiz San Millán JC, Calvo N, Rodrigo E, Moreno MA, Cotorruelo J, Conesa J, Gómez-Alamillo C, Arias M, Barrientos A.
    Transplant Proc; 2007 Sep; 39(7):2148-50. PubMed ID: 17889120
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.
    Rostaing L, Christiaans MH, Kovarik JM, Pascual J.
    Ann Transplant; 2014 Jul 14; 19():337-45. PubMed ID: 25017487
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
    Demirjian S, Stephany B, Abu Romeh IS, Boumitri M, Yamani MH, Poggio ED.
    Clin Transplant; 2009 Jul 14; 23(3):351-60. PubMed ID: 19208105
    [Abstract] [Full Text] [Related]

  • 33. Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus.
    Lamoureux F, Picard N, Boussera B, Sauvage FL, Marquet P.
    Fundam Clin Pharmacol; 2012 Aug 14; 26(4):463-72. PubMed ID: 21631587
    [Abstract] [Full Text] [Related]

  • 34. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
    Fernández A, Marcén R, Pascual J, Galeano C, Ocaña J, Arellano EM, Alfaro C, Villafruela JJ, Burgos FJ, Ortuño J.
    Transplant Proc; 2006 Oct 14; 38(8):2453-5. PubMed ID: 17097965
    [Abstract] [Full Text] [Related]

  • 35. Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12.
    van Rossum HH, Romijn FP, Smit NP, de Fijter JW, van Pelt J.
    Biochem Pharmacol; 2009 Apr 01; 77(7):1206-12. PubMed ID: 19154728
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics of sirolimus in heart transplant recipients with chronic renal impairment.
    Moloney ED, O'Mahony U, Kirwan M, McCarthy J, Hurley J, Wood AE, Egan JJ.
    Transplant Proc; 2004 Jun 01; 36(5):1547-50. PubMed ID: 15251382
    [Abstract] [Full Text] [Related]

  • 37. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure.
    Lehmkuhl H, Ross H, Eisen H, Valantine H.
    Transplant Proc; 2005 Dec 01; 37(10):4145-9. PubMed ID: 16387066
    [Abstract] [Full Text] [Related]

  • 38. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 01; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 39. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure.
    Ruiz JC, Sanchez-Fructuoso A, Rodrigo E, Conesa J, Cotorruelo JG, Gómez-Alamillo C, Calvo N, Barrientos A, Arias M.
    Transplant Proc; 2006 Oct 01; 38(8):2424-6. PubMed ID: 17097956
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients.
    Budde K, Fritsche L, Waiser J, Glander P, Slowinski T, Neumayer HH, RADW 102 Renal Transplant Study Group.
    Eur J Med Res; 2005 Apr 20; 10(4):169-74. PubMed ID: 15946913
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.